MedTrace Logo

Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

NCT05571267 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-03-13

Study results available
· View outcomes & findings →

Summary

The primary objective is to assess the safety of intravitreal (IVT) Zimura® administered in combination with anti-VEGF Therapy (AVASTIN®, EYLEA®, OR LUCENTIS®) in anti-VEGF treatment experienced subjects with neovascular age-related macular degeneration (AMD)

Conditions

  • Neovascular Age-Related Macular Degeneration

Interventions

DRUG

Avacincaptad Pegol

Zimura 2 mg, administered by intravitreal injection

DRUG

Avastin

Avastin 1.25 mg, administered by intravitreal injection

DRUG

Lucentis

Lucentis 0.5 mg, administered by intravitreal injection

DRUG

Eylea

Eylea 2 mg, administered by intravitreal injection

Sponsors & Collaborators

  • IVERIC bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · IVERIC bio, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-20
Primary Completion
2018-04-24
Completion
2018-04-24
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05571267 on ClinicalTrials.gov